Aggregation Formation in the Polyglutamine Diseases: Protection at a Cost?

Overview

Journal Mol Cells

Publisher Elsevier

Specialties Cell Biology
Molecular Biology

Date 2013 Jun 25

PMID 23794019

Citations 24

Authors

Tiffany W Todd

Janghoo Lim

Affiliations

Soon will be listed here.

Abstract

Mutant protein aggregation is a hallmark of many neurodegenerative diseases, including the polyglutamine disorders. Although the correlation between aggregation formation and disease pathology originally suggested that the visible inclusions seen in patient tissue might directly contribute to pathology, additional studies failed to confirm this hypothesis. Current opinion in the field of polyglutamine disease research now favors a model in which large inclusions are cytoprotective and smaller oligomers or misfolded monomers underlie pathogenesis. Nonetheless, therapies aimed at reducing or preventing aggregation show promise. This review outlines the debate about the role of aggregation in the polyglutamine diseases as it has unfolded in the literature and concludes with a brief discussion on the manipulation of aggregation formation and clearance mechanisms as a means of therapeutic intervention.

Citing Articles

Predicting Which Mitophagy Proteins Are Dysregulated in Spinocerebellar Ataxia Type 3 (SCA3) Using the Auto-p2docking Pipeline.

Vieira J, Barros M, Lopez-Fernandez H, Glez-Pena D, Nogueira-Rodriguez A, Vieira C Int J Mol Sci. 2025; 26(3).

PMID: 39941093 PMC: 11818632. DOI: 10.3390/ijms26031325.

Polyglutamine (PolyQ) Diseases: Navigating the Landscape of Neurodegeneration.

Tenchov R, Sasso J, Zhou Q ACS Chem Neurosci. 2024; 15(15):2665-2694.

PMID: 38996083 PMC: 11311141. DOI: 10.1021/acschemneuro.4c00184.

The structural basis of eukaryotic chaperonin TRiC/CCT: Action and folding.

Kim H, Park J, Roh S Mol Cells. 2024; 47(3):100012.

PMID: 38280673 PMC: 11004407. DOI: 10.1016/j.mocell.2024.100012.

RNA Foci Formation in a Retinal Glial Model for Spinocerebellar Ataxia Type 7.

Suarez-Sanchez R, Avila-Aviles R, Hernandez-Hernandez J, Sanchez-Celis D, Azotla-Vilchis C, Gomez-Macias E Life (Basel). 2023; 13(1).

PMID: 36675972 PMC: 9861853. DOI: 10.3390/life13010023.

The stress granule protein G3BP1 alleviates spinocerebellar ataxia-associated deficits.

Koppenol R, Conceicao A, Afonso I, Afonso-Reis R, Costa R, Tome S Brain. 2022; 146(6):2346-2363.

PMID: 36511898 PMC: 10232246. DOI: 10.1093/brain/awac473.

References

Trottier Y, Lutz Y, Stevanin G, Imbert G, Devys D, Cancel G . Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature. 1995; 378(6555):403-6. DOI: 10.1038/378403a0. View

Takahashi T, Katada S, Onodera O . Polyglutamine diseases: where does toxicity come from? what is toxicity? where are we going?. J Mol Cell Biol. 2010; 2(4):180-91. DOI: 10.1093/jmcb/mjq005. View

Paulson H, Perez M, Trottier Y, Trojanowski J, Subramony S, Das S . Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron. 1997; 19(2):333-44. DOI: 10.1016/s0896-6273(00)80943-5. View

DiFiglia M, Sapp E, Chase K, Davies S, Bates G, Vonsattel J . Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 1997; 277(5334):1990-3. DOI: 10.1126/science.277.5334.1990. View

Chafekar S, Wisen S, Thompson A, Echeverria A, Walter G, Evans C . Pharmacological tuning of heat shock protein 70 modulates polyglutamine toxicity and aggregation. ACS Chem Biol. 2012; 7(9):1556-64. PMC: 3448832. DOI: 10.1021/cb300166p. View

Bauer P, Nukina N . The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J Neurochem. 2009; 110(6):1737-65. DOI: 10.1111/j.1471-4159.2009.06302.x. View

Hammer N, Wang X, McGuffie B, Chapman M . Amyloids: friend or foe?. J Alzheimers Dis. 2008; 13(4):407-19. PMC: 2674399. DOI: 10.3233/jad-2008-13406. View

Shao J, Diamond M . Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum Mol Genet. 2007; 16 Spec No. 2:R115-23. DOI: 10.1093/hmg/ddm213. View

Waza M, Adachi H, Katsuno M, Minamiyama M, Sang C, Tanaka F . 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med. 2005; 11(10):1088-95. DOI: 10.1038/nm1298. View

10.

Tokui K, Adachi H, Waza M, Katsuno M, Minamiyama M, Doi H . 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse. Hum Mol Genet. 2008; 18(5):898-910. DOI: 10.1093/hmg/ddn419. View

11.

Muchowski P, Schaffar G, Sittler A, Wanker E, Hartl F . Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc Natl Acad Sci U S A. 2000; 97(14):7841-6. PMC: 16632. DOI: 10.1073/pnas.140202897. View

12.

Montie H, Cho M, Holder L, Liu Y, Tsvetkov A, Finkbeiner S . Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet. 2009; 18(11):1937-50. PMC: 2678926. DOI: 10.1093/hmg/ddp115. View

13.

Lotz G, Legleiter J, Aron R, Mitchell E, Huang S, Ng C . Hsp70 and Hsp40 functionally interact with soluble mutant huntingtin oligomers in a classic ATP-dependent reaction cycle. J Biol Chem. 2010; 285(49):38183-93. PMC: 2992252. DOI: 10.1074/jbc.M110.160218. View

14.

Sapp E, Penney J, Young A, Aronin N, Vonsattel J, DiFiglia M . Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease. J Neuropathol Exp Neurol. 1999; 58(2):165-73. DOI: 10.1097/00005072-199902000-00006. View

15.

Kim M, Lee H, Laforet G, McIntyre C, Martin E, Chang P . Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. J Neurosci. 1999; 19(3):964-73. PMC: 6782141. View

16.

Ordway J, Gutekunst C, Bernstein E, Cearley J, Wiener H, Dure 4th L . Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse. Cell. 1997; 91(6):753-63. DOI: 10.1016/s0092-8674(00)80464-x. View

17.

Behrends C, Langer C, Boteva R, Bottcher U, Stemp M, Schaffar G . Chaperonin TRiC promotes the assembly of polyQ expansion proteins into nontoxic oligomers. Mol Cell. 2006; 23(6):887-97. DOI: 10.1016/j.molcel.2006.08.017. View

18.

Ross C, Poirier M . Opinion: What is the role of protein aggregation in neurodegeneration?. Nat Rev Mol Cell Biol. 2005; 6(11):891-8. DOI: 10.1038/nrm1742. View

19.

Wetzel R . Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence. J Mol Biol. 2012; 421(4-5):466-90. PMC: 3362671. DOI: 10.1016/j.jmb.2012.01.030. View

20.

Saudou F, Finkbeiner S, Devys D, Greenberg M . Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell. 1998; 95(1):55-66. DOI: 10.1016/s0092-8674(00)81782-1. View